7 completed, 4 recruiting, 1 active not recruiting, 1 unknown. 8 Phase 2, 7 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Completed 5, Recruiting 2, Unknown 1 |
| Phase 1 | 7 | Completed 3, Recruiting 2, Active not recruiting 1, Unknown 1 |
Follow T-cell Prolymphocytic Leukemia: new trials by email Literature Review of T-cell Prolymphocytic Leukemia trials Research Report on T-cell Prolymphocytic Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase Ib/II Trial of Cladribine/Ruxolitinib/Venetoclax in Patients With Relapsed/Refractory T-cell Prolymphocytic Leukemia Ruxolitinib, Cladribine, Venetoclax - T-cell Prolymphocytic Leukemia, Refractory T-Cell Prolymphocytic Leukemia | Phase 1 / Phase 2 | Recruiting | M.D. Anderson Cancer Center | 36 | 2026-04-28 | 2026-08-12 |
| Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma Ruxolitinib, Positron emission tomography-computed tomography, Bone Marrow Biopsy - T-cell Lymphoma, Graft Versus Host Disease | Phase 2 | Recruiting | Jonathan Brammer | 44 | 2026-02-12 | 2026-04-15 |
| A Registry for People With T-cell Lymphoma Optional Blood Sample and Nail Sample - T-cell Lymphoma, NK-Cell Lymphoma | Recruiting | Memorial Sloan Kettering Cancer Center | 1000 | 2023-07-27 | 2026-05-20 | |
| Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older Patients Itacitinib - Leukemia, Acute, Myelodysplastic Syndromes | Phase 1 | Active not recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 32 | 2023-07-06 | 2026-10-07 |
| A Study of Ruxolitinib and Duvelisib in People With Lymphoma Ruxolitinib, Duvelisib - T-cell Lymphomas, NK-Cell Lymphomas | Phase 1 | Recruiting | Memorial Sloan Kettering Cancer Center | 70 | 2021-08-12 | 2026-09-09 |
| Letermovir for the Prevention of Cytomegalovirus Reactivation in Patients With Hematological Malignancies Treated With Alemtuzumab Letermovir - B-Cell Prolymphocytic Leukemia, Chronic Lymphocytic Leukemia | Phase 2 | Completed | Ohio State University Comprehensive Cancer Center | 6 | 2020-09-15 | 2025-02-28 |
| Itacitinib and Alemtuzumab in Treating Patients With T-Cell Prolymphocytic Leukemia Alemtuzumab, Itacitinib - Recurrent T-Cell Prolymphocytic Leukemia, T-Cell Prolymphocytic Leukemia | Phase 1 | Completed | M.D. Anderson Cancer Center | 15 | 2020-01-15 | 2024-10-10 |
| Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) and Alemtuzumab for People With Refractory or Relapsed Chronic and Acute Adult T-cell Leukemia (ATL) IL-15 plus, alemtuzumab - T-Cell Lymphoma Relapsed, Adult T-Cell Leukemia (ATL) | Phase 1 | Completed | National Cancer Institute (NCI) | 11 | 2017-01-19 | 2022-04-29 |
| CAR-pNK Cell Immunotherapy in CD7 Positive Leukemia and Lymphoma anti-CD7 CAR-pNK cells - Acute Myeloid Leukemia, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | Phase 1 / Phase 2 | Unknown | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | 10 | 2016-03-01 | 2016-12-06 |
| Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Blood Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant Allogeneic Hematopoietic Stem Cell Transplantation, Cyclosporine, Fludarabine Phosphate - Adult Acute Lymphoblastic Leukemia, Adult Acute Myeloid Leukemia | Phase 2 | Completed | Fred Hutchinson Cancer Center | 77 | 2010-12-01 | 2019-12-09 |
| Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia Allogeneic Bone Marrow Transplantation, Allogeneic Hematopoietic Stem Cell Transplantation, Autologous Hematopoietic Stem Cell Transplantation - B-Cell Prolymphocytic Leukemia, Hypodiploidy | Phase 2 | Completed | Fred Hutchinson Cancer Center | 16 | 2010-03-18 | 2019-06-11 |
| Fludarabine Phosphate and Total-Body Irradiation Before Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia Cyclosporine, Fludarabine Phosphate, Hematopoietic Cell Transplantation - B-Cell Prolymphocytic Leukemia, Chronic Lymphocytic Leukemia | Phase 2 | Completed | Fred Hutchinson Cancer Center | 21 | 2003-03-01 | 2017-12-08 |
| Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoma Autologous Hematopoietic Stem Cell Transplantation, Autologous-Allogeneic Tandem Hematopoietic Stem Cell Transplantation, Carmustine - Prolymphocytic Leukemia, Recurrent Adult Hodgkin Lymphoma | Phase 1 / Phase 2 | Completed | Fred Hutchinson Cancer Center | 76 | 1999-09-01 | 2020-01-29 |
Leukemia, Prolymphocytic, T-Cell (13) · Leukemia, Lymphocytic, Chronic, B-Cell (5) · Lymphoma, T-Cell (4) · Lymphoma, T-Cell, Cutaneous (4) · Hodgkin Disease (3) · Leukemia, Large Granular Lymphocytic (3) · Leukemia, Prolymphocytic (3) · Leukemia, Prolymphocytic, B-Cell (3) · Lymphoma, Non-Hodgkin (3) · Lymphoma, T-Cell, Peripheral (3) · Multiple Myeloma (3) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (3) · Enteropathy-Associated T-Cell Lymphoma (2) · Immunoblastic Lymphadenopathy (2) · Leukemia (2)
Hematologic Diseases (13) · Hemic and Lymphatic Diseases (13) · Immune System Diseases (13) · Immunoproliferative Disorders (13) · Leukemia, Lymphoid (13) · Leukemia, T-Cell (13) · Lymphatic Diseases (13) · Lymphoproliferative Disorders (13) · Neoplasms (13) · Neoplasms by Histologic Type (13) · Leukemia (11) · Leukemia, Prolymphocytic (10) · Lymphoma (8) · Disease Attributes (7) · Pathologic Processes (7)
Mycophenolic Acid (4) · Whole-Body Irradiation (4) · fludarabine phosphate (4) · Cyclosporine (3) · Cyclosporins (3) · Peripheral Blood Stem Cell Transplantation (3) · ruxolitinib (3) · Alemtuzumab (2) · Carmustine (2) · Cyclophosphamide (2) · Cytarabine (2) · Etoposide (2) · Melphalan (2) · carmustine, poliferprosan 20 drug combination (2) · itacitinib (2)
Fred Hutchinson Cancer Center (4) · M.D. Anderson Cancer Center (2) · Memorial Sloan Kettering Cancer Center (2) · Jonathan Brammer (1) · National Cancer Institute (NCI) (1) · Ohio State University Comprehensive Cancer Center (1) · PersonGen BioTherapeutics (Suzhou) Co., Ltd. (1) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1)
United States (12) · China (1) · Denmark (1) · Germany (1) · Italy (1)
David Maloney (2) · Alison Moskowitz, MD (1) · Brenda Sandmaier (1) · Ivana Gojo, MD (1) · John C Reneau, MD (1) · Jonathan Brammer, MD (1) · Kevin Conlon, M.D. (1) · Lin Yang, Ph.D. (1) · Mohamed Sorror (1) · Steven Horwitz, MD (1) · Tapan Kadia, MD (1) · Tapan M Kadia (1)
PMID 32499241, PMID 28054442, PMID 32508818, PMID 32603426, PMID 33883258, PMID 35475910, PMID 41536780
P30CA015704 (4), P01CA018029 (1)